Nephroblastoma is the most common type of kidney cancer in children. The prevalence rate of nephroblastoma is about 9 out of 10 kidney cancers in children. Tumors which affects only one kidney and have only one tumor are unilateral. Around 5-10% of children with nephroblastoma have more than one tumor in the same kidney. About 5% of children with nephroblastoma have tumors in both kidneys which means they have bilateral disease.
Nephroblastoma Treatment Market Analysis often become large and occasionally some newly found nephroblastoma are larger than the kidney itself. Currently scenario indicates the survival rate of children suffering from nephroblastoma is approximately 80% to 90%.
Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/5229
Segmentation
The nephroblastoma treatment is segmented based on types, drugs, diagnosis, treatment, distribution channel, and end-users.
- Based on the types, the market is segmented into favorable histology, unfavorable histology (anaplastic wilms tumor).
- Based on the drugs, the market is segmented into dactinomycin (cosmegen), doxorubicin (adriamycin), vincristine (vincasar pfs, oncovin), cyclophosphamide (cytoxan, neosar), etoposide (toposar, vepesid), irinotecan (camptosar), and others.
- Based on the diagnosis, the market is segmented into ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI), chest x-ray, bone scan, lab tests and others.
- Based on the treatment, the market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery is classified into radical nephrectomy, partial nephrectomy (nephron-sparing surgery), and others.
- Based on the distribution channel, the market is segmented into hospital pharmacies, e-commerce, drug stores, retail pharmacy, and others.
- Based on the end-user, the market is segmented into hospitals, cancer centers, surgical centers and ambulatory surgical center.
Key Players
Some of key the players in the global nephroblastoma treatment market are Bayer HealthCare LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi Pasteur Inc. (U.S.), Merck & Co. Inc. (U.S.), MediLexicon International Ltd (U.S.), Bristol-Myers Squibb Company (U.S.), Apotex Inc. (U.S.), and others.
Regional Analysis
Global nephroblastoma treatment consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas hold the largest share of the global nephroblastoma treatment market owing to the growing incidence of kidney cancers in the U.S. The Europe is the second largest market for the nephroblastoma treatment market owing to the high prevalence rate of this disease in the Eastern European regions.
Get Access Full Report @ https://www.marketresearchfuture.com/reports/nephroblastoma-treatment-market-5229
The Asia Pacific is expected to be the fastest growing region during the forecasted period 2017-2023. The incidence ratio of nephroblastoma is 1 in every 10,000 with 85% of patients usually younger than 6 years. The screening is usually performed on infants with age of 2-3 year. Girls are affected more than boys with different incidence for children of different ethnicities. For instance, the incidence rate in Asia is substantially lower than in European or American children.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future (MRFR) team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
